GSEA indicated suppression of immune activation pathways in High-risk gliomas (P.adj < 0.05, FDR < 0.25), including JAK-STAT signaling pathway, immune effector process, regulation of immune response, and leukocyte-mediated immunity (Figures 6E, F, Supplementary Table S3), suggesting an immunosuppressive microenvironment. This evidence concerns the gene SOAT1 and glioma.